Bioxydyn Limited

Bioxydyn is a global imaging contract research organization (CRO) that offers quantitative imaging services for clinical trials to support clinical drug development. Founded in 2009 and headquartered in the United Kingdom, the company specializes in magnetic resonance imaging services and works with Pharma, academic centers, and healthcare providers. It has a strong focus on quantitative imaging techniques such as oxygen-enhanced MRI (OE-MRI), dynamic contrast enhanced MRI (DCE-MRI), and diffusion MRI, with expertise in disease areas including lung, rheumatology, neurology, and oncology. Bioxydyn's capabilities and intellectual property allow it to provide advanced imaging services within a fully CFR Part 11 compliant environment. The company received a £1.20M Venture Round investment on October 4, 2012 from investors including The North West Fund, MTI Ventures, and AXM Venture Capital. This funding supports its mission to advance imaging technologies and play a crucial role in the clinical trials landscape.